U.S. Markets closed
  • S&P 500

    4,109.31
    +58.48 (+1.44%)
     
  • Dow 30

    33,274.15
    +415.12 (+1.26%)
     
  • Nasdaq

    12,221.91
    +208.43 (+1.74%)
     
  • Russell 2000

    1,802.48
    +34.10 (+1.93%)
     
  • Crude Oil

    75.70
    +1.33 (+1.79%)
     
  • Gold

    1,987.00
    -10.70 (-0.54%)
     
  • Silver

    24.24
    +0.25 (+1.03%)
     
  • EUR/USD

    1.0847
    -0.0062 (-0.5640%)
     
  • 10-Yr Bond

    3.4940
    -0.0570 (-1.61%)
     
  • Vix

    18.70
    -0.32 (-1.68%)
     
  • GBP/USD

    1.2332
    -0.0058 (-0.4686%)
     
  • USD/JPY

    132.7970
    +0.1080 (+0.0814%)
     
  • BTC-USD

    28,468.40
    -1.59 (-0.01%)
     
  • CMC Crypto 200

    621.79
    +7.58 (+1.23%)
     
  • FTSE 100

    7,631.74
    +11.31 (+0.15%)
     
  • Nikkei 225

    28,041.48
    +258.55 (+0.93%)
     

Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says

  • Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13.

  • The company is spun off of Ligand Pharmaceuticals Inc's (NASDAQ: LGNDantibody discovery business.

  • The analyst says the company is the industry's only four-species antibody discovery platform (rat, mouse, chicken, cow) with a flexible business model that can feed directly into partner labs/CROs (plug-and-play) or be utilized by OmniAb on behalf of the partners.

  • Credit Suisse says these programs validate the technology and business model, supporting steady demand averaging around 30-40 programs per year.

  • The analyst says the current valuation is assigning value to some of the 25 clinical/approved programs but not to the remaining 257 preclinical programs due to a lack of information.

  • Advancement of the existing portfolio alone should drive substantial value over time. Once a program enters the clinic, it offers non-correlated potential upside that generates cash flows at a 100% margin.

  • The company is also trading at a discount relative to other peers in the drug discovery space. The analyst writes.

  • Price Action: OABI shares are down 2.02% at $3.39 on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.